The year is half over. Here’s where the biotech industry stands

Taking stock of the drug industry, from the lab to the medicine chest

July 3, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Molly Ferguson/STAT STAT+ | The year is half over. Here's where the biotech industry stands In this week's "Adam's Biotech Scorecard," Adam also looks at a new trend: the Wall Street-to-pharma career arc. By Adam Feuerstein STAT+ | Terminated NIH grants are being reinstated almost entirely in blue states NIH grant restoration process plays out over landscape splintered by DEI restrictions, court order that applies in the blue states that sued By Anil Oza STAT+ | The biotech scorecard for the third quarter: 32 stock-moving events to watch Here is STAT's biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser